Novavax starts COVID-19 vaccine trials on children

Credit: Pixabay/CC0 Public Domain

US biotech firm Novavax said Monday it had started clinical trials of its proposed COVID-19 vaccine on children, in a program that will involve up to 3,000 adolescents aged 12-17.

Far fewer children have been sick with COVID-19 compared to adults, and most have mild to no symptoms, but they can be infected and spread the virus.

Novavax said the trials would test "the efficacy (and) safety" of the vaccine, with participants receiving either the or placebo in two doses, 21 days apart.

Participants will be monitored for up to two years after their injections.

The Novavax vaccine has not yet been authorized in any country, including for adults, but the company plans to file for emergency authorization in Britain "in the of 2021", followed by in the United States.

Novavax announced at the end of January that conducted in Britain involving 15,000 adults showed 89.3 percent efficacy.

The Novavax vaccine, which uses different technology from the doses already widely licensed around the world, is a protein-based vaccine engineered from the genetic sequence of the first strain of the coronavirus.

It can be stored at a temperature between 2 and 8 degrees Celsius (35—46.4 degrees Fahrenheit).

Other vaccine companies including Moderna, Johnson & Johnson and Pfizer are also conducting trials in adolescents.

Europe's medicines watchdog said Monday it had begun evaluating the use of Pfizer/BioNTech's for 12- to 15-year-olds, after a similar request in the United States.

Vaccine authorization for children is seen as a crucial step towards achieving herd immunity.

Explore further

Follow the latest news on the coronavirus (COVID-19) outbreak

© 2021 AFP

Citation: Novavax starts COVID-19 vaccine trials on children (2021, May 3) retrieved 18 May 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments